You are here:

2016

27. Ipsen S, Bruder R, O'Brien R, Keall PJ, Schweikard A, Poulsen PR. Online 4D ultrasound guidance for real-time motion compensation by MLC tracking. Med Phys. 2016 Oct;43(10):5695.

26. Hvid CA, Elstrøm UV, Jensen K, Alber M, Grau C. Accuracy of software-assisted contour propagation from planning CT to cone beam CT in head and neck radiotherapy. Acta Oncol. 2016 Nov;55(11):1324-1330.

25. Bert C, Kellermeier M, Tanderup K. Electromagnetic tracking for treatment verification in interstitial brachytherapy. J Contemp Brachytherapy. 2016 Oct;8(5):448-453.

24. Taasti VT, Høye EM, Hansen DC, Muren LP, Thygesen J, Skyt PS, Balling P, Bassler N, Grau C, Mierzwińska G, Rydygier M, Swakoń J, Olko P, Petersen JB. Technical Note: Improving proton stopping power ratio determination for a deformable silicone-based 3D dosimeter using dual energy CT. Med Phys. 2016 Jun;43(6):2780.

23. Stokkevåg CH, Fukahori M, Nomiya T, Matsufuji N, Engeseth GM, Hysing LB, Ytre-Hauge KS, Rørvik E, Szostak A, Muren LP. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy. Radiother Oncol. 2016 Aug;120(2):300-6.

22. Taasti VT, Petersen JB, Muren LP, Thygesen J, Hansen DC. A robust empirical parametrization of proton stopping power using dual energy CT. Med Phys. 2016 Oct;43(10):5547.

21. Bertholet J, Worm ES, Fledelius W, Høyer M, Poulsen PR. Time-Resolved Intrafraction Target Translations and Rotations During Stereotactic Liver Radiation Therapy: Implications for Marker-based Localization Accuracy. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):802-9.

20. Schmidt ML, Hoffmann L, Knap MM, Rasmussen TR, Folkersen BH, Toftegaard J, Møller DS, Poulsen PR. Cardiac and respiration induced motion of mediastinal lymph node targets in lung cancer patients throughout the radiotherapy treatment course. Radiother Oncol. 2016 Oct;121(1):52-58

19. Worm ES, Bertholet J, Høyer M, Fledelius W, Hansen AT, Larsen LP, Nielsen JE, Poulsen PR. Fiducial marker guided stereotactic liver radiotherapy: Is a time delay between marker implantation and planning CT needed? Radiother Oncol. 2016 Oct;121(1):75-78.

18. Toustrup K, Sørensen BS, Metwally MA, Tramm T, Mortensen LS, Overgaard J, Alsner J. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials. Acta Oncol. 2016 Sep-Oct;55(9-10):1091-1098.

17. Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CM, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC). Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiother Oncol. 2016 Jul 18.

16. Tanderup K, Fokdal LU, Sturdza A, Haie-Meder C, Mazeron R, van Limbergen E, Jürgenliemk-Schulz I, Petric P, Hoskin P, Dörr W, Bentzen SM, Kirisits C, Lindegaard JC, Pötter R. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol. 2016 Sep;120(3):441-446.

15. Tanderup K, Lindegaard JC, Kirisits C, Haie-Meder C, Kirchheiner K, de Leeuw A, Jürgenliemk-Schulz I, Van Limbergen E, Pötter R. Image Guided Adaptive Brachytherapy in cervix cancer: A new paradigm changing clinical practice and outcome. Radiother Oncol. 2016 Sep;120(3):365-369.

14. Hansen R, Ravkilde T, Worm ES, Toftegaard J, Grau C, Macek K, Poulsen PR. Electromagnetic guided couch and multileaf collimator tracking on a TrueBeam accelerator. Med Phys. 2016 May;43(5):2387.

13. Casares-Magaz O, van der Heide UA, Rørvik J, Steenbergen P, Muren LP. A tumour control probability model for radiotherapy of prostate cancer using magnetic resonance imaging-based apparent diffusion coefficient maps. Radiother Oncol. 2016 Apr;119(1):111-6.

12. Taasti VT, Høye EM, Hansen DC, Muren LP, Thygesen J, Skyt PS, Balling P, Bassler N, Grau C, Mierzwińska G, Rydygier M, Swakoń J, Olko P, Petersen JB. Technical Note: Improving proton stopping power ratio determination for a deformable silicone-based 3D dosimeter using dual energy CT. Med Phys. 2016 Jun;43(6):2780.

11. Stokkevåg CH, Fukahori M, Nomiya T, Matsufuji N, Engeseth GM, Hysing LB, Ytre-Hauge KS, Rørvik E, Szostak A, Muren LP. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy. Radiother Oncol. 2016 Aug;120(2):300-6.

10. Lyngholm CD, Laurberg T, Alsner J, Damsgaard TE, Overgaard J, Christiansen PM. Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort. Acta Oncol. 2016 Aug;55(8):983-92.

9. Thorsen LB, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, Zimmermann SJ, Brodersen HJ, Overgaard M, Overgaard J. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol. 2016 Feb 1;34(4):314-20.

8. Winther M, Alsner J, Tramm T, Holtved E, Baeksgaard L, Nordsmark M. Prognostic value of hypoxia-regulated gene expression in loco-regional gastroesophageal cancer. Acta Oncol. 2016 May;55(5):652-5.

7. Andreassen CN, Schack LM, Laursen LV, Alsner J. Radiogenomics - current status, challenges and future directions. Cancer Lett. 2016 Nov 1;382(1):127-136.

6. Winther M, Alsner J, Sørensen BS, Wittrup CF, Tramm T, Baeksgaard L, Hofland K, Holtved E, Nordsmark M. Hypoxia-regulated MicroRNAs in Gastroesophageal Cancer. Anticancer Res. 2016 Feb;36(2):721-30.

5. Winther M, Knudsen S, Dahlgaard J, Jensen T, Hansen A, Jensen PB, Tramm T, Alsner J, Nordsmark M. Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer. PLoS One. 2016 Feb 17;11(2):e0148070.

4. Lyhne NM, Johansen J, Kristensen CA, Andersen E, Primdahl H, Andersen LJ, Bøje CR, Jensen AR, Overgaard J. Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group. Radiother Oncol. 2016 Feb;118(2):257-66.

3. Lyhne NM, Johansen J, Kristensen CA, Andersen E, Primdahl H, Andersen LJ, Oksbjerg S, Overgaard J. Incidence of and survival after glottic squamous cell carcinoma in Denmark from 1971 to 2011-A report from the Danish Head and Neck Cancer Group. Eur J Cancer. 2016 Mar 22;59:46-56.

2. Pagh A, Grau C, Overgaard J. Failure pattern and salvage treatment after radical treatment of head and neck cancer. Acta Oncol. 2016 May;55(5):625-32.

1. Ravn S, Holmberg M, Sørensen P, Frokjaer JB, Carl J. Presurgical functional magnetic resonance imaging in patients with brain tumors. Acta Radiol. 2016 Jan;57(1):82-9.